Evidence map›Paper›PMID 36077657›Full record

ArticleCancers2022

Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection.

Bonil Koo, Dohoon Lee, Sangseon Lee, Inyoung Sung, Sun Kim, Sunho Lee

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bonil KooInterdisciplinary Program in Bioinformatics, Seoul National University, Seoul 08826, Korea.ORCID 0000-0003-4357-1850
Dohoon LeeBioinformatics Institute, Seoul National University, Seoul 08826, Korea.ORCID 0000-0003-2163-5489
Sangseon LeeInstitute of Computer Technology, Seoul National University, Seoul 08826, Korea.ORCID 0000-0002-7398-9580
Inyoung SungInterdisciplinary Program in Bioinformatics, Seoul National University, Seoul 08826, Korea.ORCID 0000-0002-2681-9722
Sun KimInterdisciplinary Program in Bioinformatics, Seoul National University, Seoul 08826, Korea.ORCID 0000-0001-5385-9546
Sunho LeeAIGENDRUG Co., Ltd., Seoul 08826, Korea.ORCID 0000-0001-9534-3337

Funding

a grant from Ministry of Food and Drug Safety in 2022 DY0002258224Institute of Information & communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (MSIT) NO.2021-0-01343the Bio & Medical Technology Development Program of the NRF NRF-2019M3E5D307337511the Collaborative Genome Program for Fostering New Post-Genome Industry of the National Research Foundation (NRF) funded by the Ministry of Science and ICT (MSIT) NRF-2014M3C9A3063541
6 · The paper itself

Abstract

Patient stratification is a clinically important task because it allows us to establish and develop efficient treatment strategies for particular groups of patients. Molecular subtypes have been successfully defined using transcriptomic profiles, and they are used effectively in clinical practice, e.g., PAM50 subtypes of breast cancer. Survival prediction contributed to understanding diseases and also identifying genes related to prognosis. It is desirable to stratify patients considering these two aspects simultaneously. However, there are no methods for patient stratification that consider molecular subtypes and survival outcomes at once. Here, we propose a methodology to deal with the problem. A genetic algorithm is used to select a gene set from transcriptome data, and their expression quantities are utilized to assign a risk score to each patient. The patients are ordered and stratified according to the score. A gene set was selected by our method on a breast cancer cohort (TCGA-BRCA), and we examined its clinical utility using an independent cohort (SCAN-B). In this experiment, our method was successful in stratifying patients with respect to both molecular subtype and survival outcome. We demonstrated that the orders of patients were consistent across repeated experiments, and prognostic genes were successfully nominated. Additionally, it was observed that the risk score can be used to evaluate the molecular aggressiveness of individual patients.

Indexed as

gene set selectiongenetic algorithmmolecular subtypepatient stratificationsurvival outcome

Identifiers

PMID36077657
PMCPMC9454699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.